Helus Pharma Appoints Dr. Ken Kramer as SVP, Medical Affairs

Helus Pharma, a clinical stage pharmaceutical company developing novel serotonergic agonists (NSAs), has appointed Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs, effective immediately.

Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programs, including global launch readiness, evidence generation, and engagement with key opinion leaders. Most recently, he served as Vice President and Head of Medical Neuroscience at Bristol Myers Squibb, where he led an integrated medical strategy team to successfully launch the first new treatment for schizophrenia in over seven decades.

“Strong medical leadership is vital to how we connect with and serve the scientific and clinical communities,” said Michael Cola, CEO of Helus Pharma. “Dr. Kramer brings both deep experience and an execution mindset to help us scale medical capabilities and advance our pipeline. His leadership will be instrumental in translating strong science into meaningful engagement with patients, providers, and payors.”

Experience

At Karuna Therapeutics, as VP and Head of Medical Affairs, Kramer built and expanded medical capabilities during a period of significant organizational growth and supported the organization through its acquisition. Earlier in his career, he spent more than a decade leading U.S. psychiatry medical affairs teams at AbbVie and its predecessor organizations, contributing to multiple successful product launches. He began his career in academic medicine as an Assistant Professor of Psychiatry.

Kramer holds a Ph.D. in Neuropharmacology from New York University and an M.S. in Neuroscience and a B.S. in Biology from the University of Rochester.

“Helus is driving innovation in its field through the strength of its science and its commitment to advancing NSAs as a differentiated approach to treating complex neuropsychiatric disorders,” said Kramer. “Joining Helus at this stage, where strong medical leadership can deepen scientific engagement and further evolve the organization’s medical capabilities, is incredibly meaningful to me. I look forward to collaborating across Helus to translate their innovative science into meaningful understanding for clinicians and, ultimately, better outcomes for patients.”